Bellicum Pharmaceuticals (FRA:BPXA) Accumulated other comprehensive income (loss) : €-0.33 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Bellicum Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2023 was €-0.33 Mil.

Bellicum Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Mar. 2023 (€-0.33 Mil) to Jun. 2023 (€-0.33 Mil) but then declined from Jun. 2023 (€-0.33 Mil) to Sep. 2023 (€-0.33 Mil).

Bellicum Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2020 (€-0.28 Mil) to Dec. 2021 (€-0.30 Mil) and declined from Dec. 2021 (€-0.30 Mil) to Dec. 2022 (€-0.33 Mil).

Bellicum Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Bellicum Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Bellicum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-0.13

-0.29

-0.28

-0.30

-0.33

Bellicum Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.36	-0.33	-0.33	-0.33	-0.33

Bellicum Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Bellicum Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

BLCM:USA

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines